Denali Therapeutics Stock Today
| DNLI Stock | USD 21.45 0.04 0.19% |
Performance0 of 100
| Odds Of DistressLess than 8
|
Denali Therapeutics is trading at 21.45 as of the 23rd of December 2024. This is a 0.19 percent decrease since the beginning of the trading day. The stock's open price was 21.49. Denali Therapeutics has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of November 2024 and ending today, the 23rd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of December 2017 | Category Healthcare | Classification Health Care |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. The company has 143.92 M outstanding shares of which 7.37 M shares are currently shorted by private and institutional investors with about 7.68 trading days to cover. More on Denali Therapeutics
Moving together with Denali Stock
Moving against Denali Stock
Denali Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Ryan Watts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDenali Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Denali Therapeutics' financial leverage. It provides some insight into what part of Denali Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Denali Therapeutics (DNLI) is traded on NASDAQ Exchange in USA. It is located in 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 390 people. Denali Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.09 B. Denali Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 143.92 M outstanding shares of which 7.37 M shares are currently shorted by private and institutional investors with about 7.68 trading days to cover.
Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66.
Check Denali Therapeutics Probability Of Bankruptcy
Ownership AllocationDenali Therapeutics holds a total of 143.92 Million outstanding shares. The majority of Denali Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Denali Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Denali Therapeutics. Please pay attention to any change in the institutional holdings of Denali Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost one million five hundred twenty-five thousand five hundred seventy-three invesors are currently shorting Denali Therapeutics expressing very little confidence in its future performance.
Check Denali Ownership Details
Denali Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alliancebernstein L.p. | 2024-09-30 | 3 M | |
| Geode Capital Management, Llc | 2024-09-30 | 3 M | |
| T. Rowe Price Associates, Inc. | 2024-09-30 | 2.9 M | |
| Camber Capital Management Llc | 2024-09-30 | 2 M | |
| Marshall Wace Asset Management Ltd | 2024-09-30 | 2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.7 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.6 M | |
| Goldman Sachs Group Inc | 2024-09-30 | 1.4 M | |
| Bank Of New York Mellon Corp | 2024-09-30 | 1.3 M | |
| Baillie Gifford & Co Limited. | 2024-09-30 | 13.3 M | |
| Blackrock Inc | 2024-06-30 | 13.2 M |
Denali Therapeutics Historical Income Statement
Denali Stock Against Markets
Denali Therapeutics Corporate Management
| Peter Chin | Senior Affairs | Profile | |
| Carole MD | Chief Development | Profile | |
| Mark Rowen | Vice Development | Profile | |
| Chris Walsh | General Counsel | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.